NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

脂質調節藥的全球市場的成長:趨勢及預測(2017年∼2022年)

Lipid Regulators Market - Growth, Trends & Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 391364
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
脂質調節藥的全球市場的成長:趨勢及預測(2017年∼2022年) Lipid Regulators Market - Growth, Trends & Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

脂質調節藥,用作血脂異常症、心血管障礙、骨質疏鬆症、更年期後的併發症等的治療。因此,脂質調整藥大部分分類在處方藥等級。根據調查,每年有2億5,540萬件以上這樣的這些他汀類藥物調劑。完全及非他汀類藥物的脂質調節藥活化他汀類藥物市場。

本報告提供全球脂質調節藥市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 關於報告
  • 調查方法

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 市場成長要素
    • 日益積極的指南
    • 治療人口的增加
    • 高齡人口
    • 進行中的治療藥的需求
    • 病人依從性改善
    • 政府的輔助
  • 市場阻礙因素
    • 對脂質調節藥的認識低
    • 未遵守醫生的NCEP指南
    • 複合藥的引進
    • 低成本非專利的引進
  • 市場機會
  • 市場威脅

第4章 波特五力分析

  • 供應商談判力
  • 買主談判力
  • 競爭度
  • 替代品的威脅
  • 新加入廠商的威脅

第5章 市場區隔

  • 各類型
    • 他汀類
    • 非他汀類
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
      • 印度
      • 中國
      • 日本
      • 新加坡
      • 其他

第6章 競爭情形

第7章 企業簡介

  • Abbott Laboratories
  • Andrx Corporation
  • Astrazeneca
  • Atellas Pharma, Inc.
  • Bristol-Myers Squibb
  • Bentley Pharmaceuticals
  • Merck
  • Novartis
  • Pfizer
  • Teva Pharmaceuticals

第8章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 48558

Lipids are important biomolecules, for example cholesterol acts as precursor for steroid hormones and bile acids. However, any kind of lipid in excess is not good for health. Lipid regulators, apart from cholesterol control, deal with fragile bones with high susceptibility to break which is termed as Osteoporosis and also they keep a check on myocardial infarctions which is commonly known as heart attack.

Recently due to increase in prevalence of diseases like Dyslipidemia, have increased the demand for lipid regulators. Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke or other circulatory concerns, especially in smokers. Moreover, geriatric population is more prone to cardiovascular diseases. In the elderly age group, lipid-altering medication has been proven to reduce cardiovascular risk.

Hence, these factors are helping the growth of the market. However, lack of awareness regarding the lipid regulators and presence of low-cost generics have been hindering the market growth.

Key Market Trends

Statins Segment are Expected to Dominate the Market

Dyslipidemia, defined as elevated total or low-density lipoprotein (LDL) cholesterol levels, or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for coronary heart disease (CHD) and stroke. The prevalence of dyslipidemia increases in diabetic population.

According to a report by Yaru Li et al., published in PLoS One Journal 2018, the prevalence of dyslipidemia in the Chinese population was 39.9%, 46.8%, and 59.3% in population with normal glucose, prediabetes, and type 2 diabetes mellitus (T2DM). Moreover, the diabetic population has increased over the years.

As per a World Health Organization 2018 report, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014, resulting in a rise in global prevalence of diabetes among adults over 18 years of age from 4.7% in 1980 to 8.5% in 2014. Hence, the increasing prevalence of diabetes may result in increasing prevalence of dyslipidemia.

The statins competitively inhibit HMG-CoA reductase. Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration. Hence, the demand for statins is expected to increase as prevalence of dyslipidemia increases.

In addition, the lipid regulatory market is being dominated by statin and most of the statin drugs patents are coming to an end and there would be an increased competition in the generics.

North America is Expected to Dominate the Lipid Regulators Market

According to OECD, the North American countries of United States and Mexico have one of the highest prevalence of Obesity and Diabetes in the world. Moreover, being overweight or obese increases the chances of developing the common type of diabetes, type 2 diabetes. As the presence of diabetes increases the risk of dyslipidemia, its prevalence is expected to increase.

However, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

Majority of the lipid regulators are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Diabetes and Cardiac Diseases
    • 4.2.2 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Low Awareness of Lipid Regulators
    • 4.3.2 Introduction of low cost generics
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Statins
      • 5.1.1.1 Branded statins
      • 5.1.1.2 Statin combinations
      • 5.1.1.3 Generic statins
    • 5.1.2 Non-statins
      • 5.1.2.1 Fibric-acid derivatives
      • 5.1.2.2 Bile-acid sequestrants
      • 5.1.2.3 Nicotinic acid derivatives
      • 5.1.2.4 Other new products
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc
    • 6.1.2 Amgen
    • 6.1.3 Andrx Corporation
    • 6.1.4 AstraZeneca
    • 6.1.5 Bristol-Myers Squibb
    • 6.1.6 Merck KGaA
    • 6.1.7 Novartis
    • 6.1.8 Pfizer
    • 6.1.9 Teva Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS